title: Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.
authors.forename: Sorilla
authors.initials: S
authors.lastname: Prey
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Robert
authors.forename: Mireille
authors.initials: M
authors.lastname: Drouet
authors.forename: Agnés
authors.initials: A
authors.lastname: Sparsa
authors.forename: Cyril
authors.initials: C
authors.lastname: Roux
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Bonnetblanc
authors.forename: Christophe
authors.initials: C
authors.lastname: Bédane
mesh_terms: D000369:Aged, 80 and over; D000068800:Etanercept; D005128:Eye Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010390:Pemphigoid, Benign Mucous Membrane / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept